{"id":"tacrolimus-atg","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity (tremor, headache, seizures)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Serum sickness (ATG)"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to FK-binding protein and inhibits calcineurin phosphatase, preventing T-cell receptor signaling and IL-2 production. ATG is a polyclonal immunoglobulin derived from immunized animals that binds to T-cell surface antigens, leading to complement-mediated lysis and T-cell depletion. This combination provides synergistic immunosuppression for transplant rejection prevention.","oneSentence":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation, while ATG (antithymocyte globulin) is a polyclonal antibody that depletes T lymphocytes, together providing potent immunosuppression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:51.289Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in solid organ transplantation"},{"name":"Prevention and treatment of graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT07412470","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-03-13","conditions":"Kidney Transplant Rejection","enrollment":526},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT06705062","phase":"PHASE3","title":"Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease","enrollment":316},{"nctId":"NCT04644016","phase":"PHASE2","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-20","conditions":"AML, ALL, MDS","enrollment":31},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT06365437","phase":"PHASE2","title":"A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation","status":"TERMINATED","sponsor":"ITB-Med LLC","startDate":"2021-06-06","conditions":"Kidney Transplantation","enrollment":33},{"nctId":"NCT04965597","phase":"PHASE2","title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-04-19","conditions":"Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia","enrollment":40},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT03249831","phase":"PHASE1","title":"A Blood Stem Cell Transplant for Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-01-04","conditions":"Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies","enrollment":3},{"nctId":"NCT06055608","phase":"PHASE2","title":"Advancing Transplantation Outcomes in Children","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-22","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT05156710","phase":"PHASE2","title":"BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-09","conditions":"Transplant Rejection","enrollment":48},{"nctId":"NCT06517641","phase":"PHASE2","title":"Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-05-12","conditions":"Severe Aplastic Anemia","enrollment":60},{"nctId":"NCT00882895","phase":"PHASE2","title":"Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2009-05-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":18},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT05669001","phase":"PHASE2","title":"A Study of TCD601 in de Novo Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITB-Med LLC","startDate":"2023-12-28","conditions":"Renal Transplantation","enrollment":76},{"nctId":"NCT03121014","phase":"PHASE2","title":"Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-04-24","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT07249346","phase":"PHASE2","title":"Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Hannah Choe, MD","startDate":"2026-06-01","conditions":"Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia","enrollment":124},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT02377193","phase":"PHASE4","title":"Simulect Versus ATG in Sensitized Renal Transplant Patient","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2013-09","conditions":"Renal Transplant Rejection","enrollment":60},{"nctId":"NCT05525507","phase":"PHASE1","title":"Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2022-12-21","conditions":"End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection","enrollment":10},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT03320642","phase":"PHASE1","title":"GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-02-27","conditions":"Hematologic Malignancies","enrollment":84},{"nctId":"NCT03841097","phase":"PHASE4","title":"Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roy D. Bloom, MD","startDate":"2019-11-11","conditions":"Kidney Transplant; Complications","enrollment":60},{"nctId":"NCT06315309","phase":"PHASE2","title":"Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-15","conditions":"GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes","enrollment":29},{"nctId":"NCT06265584","phase":"PHASE2","title":"Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-08","conditions":"Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders","enrollment":56},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT02790515","phase":"PHASE2","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-07-14","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma","enrollment":170},{"nctId":"NCT04530487","phase":"PHASE2","title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-19","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor","enrollment":1},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT06949267","phase":"EARLY_PHASE1","title":"A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-01","conditions":"Acute Graft-versus-Host Disease","enrollment":56},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT01701986","phase":"PHASE1, PHASE2","title":"Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-25","conditions":"Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":64},{"nctId":"NCT04311632","phase":"PHASE2","title":"A Dose Escalation Study in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"ITB-Med LLC","startDate":"2021-05-26","conditions":"Kidney Transplantation","enrollment":13},{"nctId":"NCT01265537","phase":"NA","title":"A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-06-24","conditions":"Acute Graft Rejection, Diabetes","enrollment":30},{"nctId":"NCT02274662","phase":"PHASE4","title":"Expanded Access Protocol Thymus Transplantation","status":"COMPLETED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2014-08","conditions":"Poor Thymic Function, Immunodeficiency, Athymia","enrollment":11},{"nctId":"NCT04521946","phase":"PHASE1","title":"Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-14","conditions":"Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Germ Cell Tumor","enrollment":""},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT02582775","phase":"PHASE2","title":"MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-03","conditions":"Epidermolysis Bullosa","enrollment":17},{"nctId":"NCT03225417","phase":"PHASE1, PHASE2","title":"Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2017-05-16","conditions":"Hematopoietic Stem Cell Transplantation, Multiple Myeloma","enrollment":142},{"nctId":"NCT04009525","phase":"PHASE4","title":"Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2019-07-05","conditions":"Thalassemia Major","enrollment":823},{"nctId":"NCT01664910","phase":"PHASE1, PHASE2","title":"CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-29","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":27},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT03605654","phase":"PHASE2, PHASE3","title":"Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants","status":"WITHDRAWN","sponsor":"Medeor Therapeutics, Inc.","startDate":"2024-12","conditions":"Kidney Transplant Rejection","enrollment":""},{"nctId":"NCT01751997","phase":"PHASE2, PHASE3","title":"Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors","status":"COMPLETED","sponsor":"Byung-Sik Cho","startDate":"2013-01","conditions":"Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT04936971","phase":"PHASE4","title":"Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response","status":"WITHDRAWN","sponsor":"Edoardo Melilli","startDate":"2021-09","conditions":"Kidney Transplantation, Cytomegalovirus Infections","enrollment":""},{"nctId":"NCT02441803","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Leukemia","enrollment":11},{"nctId":"NCT06196996","phase":"NA","title":"Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2021-09-14","conditions":"Brittle Type 1 Diabetes Mellitus","enrollment":18},{"nctId":"NCT03734601","phase":"PHASE2","title":"Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-11-05","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder","enrollment":22},{"nctId":"NCT05126849","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-01-06","conditions":"Refractory Idiopathic Aplastic Anemia, Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":31},{"nctId":"NCT00611351","phase":"PHASE2","title":"Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2005-06-07","conditions":"Graft Versus Host Disease, Leukemia, Lymphoma","enrollment":5},{"nctId":"NCT03096782","phase":"PHASE2","title":"Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-13","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia","enrollment":6},{"nctId":"NCT01172418","phase":"PHASE4","title":"Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols","status":"COMPLETED","sponsor":"University of Miami","startDate":"2006-02","conditions":"Transplant; Failure, Kidney","enrollment":200},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT02661035","phase":"PHASE2","title":"Allo HSCT Using RIC for Hematological Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-03-09","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":156},{"nctId":"NCT02122081","phase":"PHASE1","title":"Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","status":"COMPLETED","sponsor":"Sumithira Vasu","startDate":"2015-07-27","conditions":"Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","enrollment":33},{"nctId":"NCT00556933","phase":"PHASE4","title":"Improved Induction and Maintenance Immunosuppression in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-04-01","conditions":"End-stage Renal Disease","enrollment":180},{"nctId":"NCT01044745","phase":"PHASE2","title":"Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-12-10","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":20},{"nctId":"NCT05385432","phase":"PHASE3","title":"Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2023-09-12","conditions":"Renal Transplant Rejection, Induction Therapy","enrollment":244},{"nctId":"NCT05973734","phase":"PHASE1","title":"Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2023-10-01","conditions":"Islet Transplantation","enrollment":24},{"nctId":"NCT06000982","phase":"PHASE3","title":"Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-10-01","conditions":"GVHD","enrollment":138},{"nctId":"NCT02936505","phase":"NA","title":"Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2016-10-12","conditions":"Lung Transplantation, Allografts","enrollment":249},{"nctId":"NCT03468478","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2017-06-18","conditions":"Kidney Transplant Infection","enrollment":1209},{"nctId":"NCT04903054","phase":"PHASE2","title":"Selective CD28 Blockade in Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-01-10","conditions":"Kidney Transplantation, Renal Transplant Recipients","enrollment":""},{"nctId":"NCT05739630","phase":"PHASE2, PHASE3","title":"M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-01","conditions":"Acute Leukemia","enrollment":60},{"nctId":"NCT00995059","phase":"PHASE1, PHASE2","title":"Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"","conditions":"Multiple Myeloma, Refractory Multiple Myeloma","enrollment":""},{"nctId":"NCT02158052","phase":"NA","title":"Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-02","conditions":"Multiple Myeloma, Amyloidosis","enrollment":2},{"nctId":"NCT02918292","phase":"PHASE2","title":"Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-07-03","conditions":"Severe Aplastic Anemia","enrollment":32},{"nctId":"NCT03388008","phase":"PHASE2","title":"Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-12-17","conditions":"Lung Transplant Rejection, Antibody-mediated Rejection","enrollment":27},{"nctId":"NCT02495077","phase":"PHASE2","title":"Effects of Inhibiting Early Inflammation in Kidney Transplant Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-02","conditions":"Kidney Transplant","enrollment":290},{"nctId":"NCT01168219","phase":"PHASE2","title":"Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-15","conditions":"Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia","enrollment":68},{"nctId":"NCT02833805","phase":"PHASE2","title":"NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09","conditions":"Severe Aplastic Anemia, Aplastic Anemia, Bone Marrow Failure","enrollment":21},{"nctId":"NCT05303727","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08","conditions":"Neuroblastoma","enrollment":64},{"nctId":"NCT02821026","phase":"PHASE1, PHASE2","title":"Omental Islet Transplant","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-05","conditions":"Type 1 Diabetes","enrollment":4},{"nctId":"NCT03099122","phase":"PHASE4","title":"A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-08-16","conditions":"End-stage Renal Disease","enrollment":115},{"nctId":"NCT00579527","phase":"PHASE1, PHASE2","title":"Phase I/II Thymus Transplantation With Immunosuppression #950","status":"COMPLETED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2005-12-19","conditions":"DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly","enrollment":14},{"nctId":"NCT05294822","phase":"NA","title":"Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-09-30","conditions":"Diabetes","enrollment":20},{"nctId":"NCT01471444","phase":"PHASE3","title":"Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-11-02","conditions":"Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection","enrollment":256},{"nctId":"NCT02314403","phase":"PHASE1","title":"Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-02","conditions":"Kidney Failure, Chronic, Renal Insufficiency","enrollment":2},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT00919503","phase":"PHASE2","title":"Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-07-31","conditions":"Non-Neoplastic Hematologic and Lymphocytic Disorder","enrollment":98},{"nctId":"NCT01020539","phase":"PHASE1","title":"Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09-11","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia","enrollment":18},{"nctId":"NCT01729494","phase":"PHASE4","title":"Belatacept Early Steroid Withdrawal Trial","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-09","conditions":"Renal Transplantation","enrollment":316},{"nctId":"NCT01790594","phase":"PHASE2","title":"Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-02","conditions":"Simultaneous Kidney and Pancreas Transplantation","enrollment":46},{"nctId":"NCT03602898","phase":"PHASE2","title":"Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-06-01","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia","enrollment":""},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT04118075","phase":"PHASE2","title":"PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2019-01-01","conditions":"GVHD, Acute","enrollment":23},{"nctId":"NCT02129582","phase":"PHASE1","title":"Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-11-05","conditions":"Acute Myeloid Leukemia, Hematologic Malignancies, Acute Lymphocytic Leukemia","enrollment":14},{"nctId":"NCT01685411","phase":"NA","title":"Busulfan and Cyclophosphamide Followed By ALLO BMT","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":5},{"nctId":"NCT01220856","phase":"PHASE2","title":"Reparixin in Pancreatic Islet Transplantation","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2010-07-28","conditions":"Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus","enrollment":9},{"nctId":"NCT00813124","phase":"PHASE2","title":"Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-12","conditions":"Stem Cell Transplantation, Leukemia","enrollment":24},{"nctId":"NCT02152345","phase":"PHASE4","title":"Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-06","conditions":"Implant or Graft; Rejection","enrollment":57},{"nctId":"NCT04114188","phase":"PHASE2","title":"Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2016-12-15","conditions":"Renal Transplant Rejection","enrollment":68},{"nctId":"NCT03828058","phase":"PHASE2","title":"Envarsus XL Immunosuppression Following Liver Transplantation","status":"COMPLETED","sponsor":"Methodist Healthcare","startDate":"2019-04-01","conditions":"Recipients of Liver Transplant","enrollment":110},{"nctId":"NCT02083991","phase":"PHASE4","title":"Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2013-01","conditions":"Diabetes Mellitus","enrollment":224},{"nctId":"NCT01856257","phase":"PHASE2","title":"Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-07","conditions":"Primary Renal Allograft Candidate, Kidney Transplantation","enrollment":71},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT03292445","phase":"EARLY_PHASE1","title":"Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation","status":"UNKNOWN","sponsor":"Samuel Strober","startDate":"2017-02-14","conditions":"Immune Tolerance","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":338,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Thymoglobuline"],"phase":"marketed","status":"active","brandName":"tacrolimus, ATG","genericName":"tacrolimus, ATG","companyName":"University Hospital, Toulouse","companyId":"university-hospital-toulouse","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus is a small molecule inhibitor of the peptidyl-prolyl cis-trans isomerase FKBP1A, which is involved in the mechanism of action. It is used in the treatment of various conditions, including Type 1 Diabetes, Leukemia, Lymphoma, and Blood And Marrow Transplantation, often in combination with other interventions such as Melphalan and Fludarabine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}